222 related articles for article (PubMed ID: 12854093)
21. First AIDS vaccine trial launched.
Science; 1998 Jun; 280(5370):1697. PubMed ID: 9660708
[No Abstract] [Full Text] [Related]
22. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.
Follmann D; Duerr A; Tabet S; Gilbert P; Moodie Z; Fast P; Cardinali M; Self S
J Acquir Immune Defic Syndr; 2007 Jan; 44(1):49-60. PubMed ID: 17075387
[TBL] [Abstract][Full Text] [Related]
23. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of vaccination against hepatitis B in adult with HIV infection].
Kalinowska-Nowak A; Bociaga-Jasik M; Garlicki A; Mach T
Przegl Epidemiol; 2007; 61(2):339-47. PubMed ID: 17956052
[TBL] [Abstract][Full Text] [Related]
25. Outstanding questions on HIV vaccine trial.
Jefferys R; Harrington M
Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
[No Abstract] [Full Text] [Related]
26. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
Egan MA
Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
[No Abstract] [Full Text] [Related]
27. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM; Forthal DN; Harro CD; Judson FN; Mayer KH; Para MF;
J Infect Dis; 2005 Mar; 191(5):654-65. PubMed ID: 15688278
[TBL] [Abstract][Full Text] [Related]
28. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
29. Mathematical study of a staged-progression HIV model with imperfect vaccine.
Gumel AB; McCluskey CC; van den Driessche P
Bull Math Biol; 2006 Nov; 68(8):2105-28. PubMed ID: 16868850
[TBL] [Abstract][Full Text] [Related]
30. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
Hudgens MG
Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
32. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
Longini IM; Datta S; Halloran ME
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
[TBL] [Abstract][Full Text] [Related]
33. Fifty volunteer for live-vaccine trial.
James JS
AIDS Treat News; 1997 Oct; (No 280):1-2. PubMed ID: 11364735
[TBL] [Abstract][Full Text] [Related]
34. Potential public health impact of imperfect HIV type 1 vaccines.
Anderson R; Hanson M
J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
[TBL] [Abstract][Full Text] [Related]
35. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
[TBL] [Abstract][Full Text] [Related]
36. Statistical evaluation of HIV vaccines in early clinical trials.
Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
[TBL] [Abstract][Full Text] [Related]
38. Virology. Moving forward in HIV vaccine development.
Letvin NL
Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
[No Abstract] [Full Text] [Related]
39. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
40. National vaccine effort seen as insufficient.
AIDS Alert; 1998 Jan; 13(1):4-6. PubMed ID: 11364864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
